GO:2000752 regulation of glucosylceramide catabolic process: Sphingolipid Breakdown Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000752 describes any process that modulates the frequency, rate or extent of glucosylceramide catabolic process, the breakdown of glucosylceramide (GlcCer) into ceramide and glucose.
• Glucosylceramide catabolism is the final degradative step of the glycosphingolipid pathway and is essential for maintaining the balance between complex glycosphingolipids and ceramide.
• Key enzymes include glucocerebrosidase (GBA1), which hydrolyzes GlcCer to ceramide, and its regulators such as saposin C and GM2 activator protein.
• Dysregulation of glucosylceramide catabolism is linked to Gaucher disease, Parkinson disease, and other neurodegenerative disorders.
• Regulation occurs at multiple levels, including Golgi-localized phosphoinositides, ABCC10-mediated efflux, and transcriptional control of sphingolipid enzymes.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are powerful tools to dissect the causal roles of genes regulating this process.
Description
Glucosylceramide (GlcCer) is the simplest glycosphingolipid and a central intermediate in sphingolipid metabolism. Its catabolic breakdown, termed glucosylceramide catabolic process, releases ceramide and glucose and is critical for cellular homeostasis. The Gene Ontology term GO:2000752, regulation of glucosylceramide catabolic process, encompasses any molecular event that modulates the frequency, rate, or extent of this degradation. Understanding this regulatory node is important because imbalances in GlcCer and ceramide levels contribute to lysosomal storage disorders, neurodegeneration, and cancer. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of the term, its genetic players, disease relevance, and experimental strategies.
regulation of glucosylceramide catabolic process At A Glance
| GO ID | GO:2000752 |
|---|---|
| GO term | regulation of glucosylceramide catabolic process |
| Ontology | biological_process |
| Synonym | regulation of glucosylceramide breakdown; regulation of glucosylceramide catabolism; regulation of glucosylceramide degradation |
| Major function | Modulates the rate of glucosylceramide degradation, thereby controlling ceramide and glycosphingolipid levels |
| Key enzymes | Glucocerebrosidase (GBA1), saposin C, GM2 activator protein |
| Regulatory inputs | Golgi phosphoinositides, ABCC10, transcriptional factors |
| Disease relevance | Gaucher disease, Parkinson disease, neurodegeneration |
What Is GO:2000752?
GO:2000752 is a biological process term defined as any process that modulates the frequency, rate or extent of glucosylceramide catabolic process. In other words, it covers the regulatory inputs that control the enzymatic breakdown of glucosylceramide into ceramide and glucose, including changes in enzyme activity, expression, localization, or substrate availability.
Why Is regulation of glucosylceramide catabolic process Important in Cell Biology?
Regulation of glucosylceramide catabolic process is critical because it determines the cellular balance between glucosylceramide and ceramide, two lipids with distinct signaling and structural roles. Disruption of this balance leads to lysosomal storage pathologies, neuroinflammation, and altered membrane dynamics, making this regulatory node a therapeutic target.
• Maintains lysosomal homeostasis by preventing glucosylceramide accumulation.
• Controls ceramide levels, which influence apoptosis, autophagy, and stress responses.
• Mutations in GBA1, the enzyme that catabolizes glucosylceramide, are the most common genetic risk factor for Parkinson disease.
• Defective catabolism causes Gaucher disease, a lysosomal storage disorder.
• Regulation by Golgi phosphoinositides links lipid signaling to glycosphingolipid breakdown.
• ABCC10-mediated efflux modulates glucosylceramide levels and drug resistance.
• Sphingolipid-enriched domains in fungi rely on regulated catabolism for membrane organization.
• Altered glucosylceramide catabolism is implicated in renal fibrosis and neurodegeneration.
• Provides targets for pharmacological chaperones and substrate reduction therapies.
• Enables precise CRISPR-based dissection of regulatory networks.
What Happens During regulation of glucosylceramide catabolic process?
Substrate recognition and lysosomal targeting
In simple terms: The cell first delivers glucosylceramide to the lysosome where it can be broken down.
Glucosylceramide catabolism occurs primarily in the lysosome. GlcCer is delivered to lysosomes via vesicular trafficking or by direct transfer from the plasma membrane. The lipid is presented to the degradative enzyme glucocerebrosidase (GBA1) with the help of saposin C, a small activator protein that binds and solubilizes GlcCer. Regulation at this step includes control of lysosomal targeting and saposin C availability.
Enzymatic hydrolysis by glucocerebrosidase
In simple terms: The enzyme GBA1 cuts glucosylceramide into ceramide and glucose.
GBA1 hydrolyzes the beta-glucosidic bond of glucosylceramide, releasing ceramide and glucose. This reaction is the defining step of glucosylceramide catabolic process. Its rate is modulated by pH, lipid environment, and accessory proteins such as saposin C and GM2 activator protein. Regulation of GBA1 activity directly controls the flux through this pathway.
Regulation by Golgi-localized phosphoinositides
In simple terms: Lipid signals in the Golgi can turn glucosylceramide production up or down, indirectly affecting its breakdown.
Golgi-localized phosphoinositides regulate glucosylceramide synthesis, and changes in synthesis alter the pool available for catabolism. This cross-talk between anabolic and catabolic arms ensures balanced sphingolipid levels. The regulatory mechanism involves phosphoinositide-binding proteins that control enzyme recruitment and activity.
Efflux and membrane transport regulation
In simple terms: Transporters can pump glucosylceramide out of cells, changing how much is available to be degraded.
ABCC10, a member of the ATP-binding cassette transporter family, differentially regulates glucosylceramide synthesis and efflux at the Golgi and plasma membrane. By modulating GlcCer efflux, ABCC10 influences the substrate pool for catabolism. This represents a regulatory layer that couples lipid transport to degradation.
Transcriptional and post-translational control
In simple terms: Cells can adjust the amount or activity of breakdown enzymes by turning genes on or off or modifying proteins.
Expression of GBA1 and other sphingolipid enzymes is subject to transcriptional regulation, and their activities are further tuned by post-translational modifications. For example, nicotinamide increases ceramide biosynthesis and can indirectly affect glucosylceramide catabolism by altering substrate availability. Such multilayered control ensures rapid adaptation to metabolic demands.
Key Genes Involved in GO:2000752 regulation of glucosylceramide catabolic process
The following genes and proteins are central to the regulation of glucosylceramide catabolic process, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GBA1 | Encodes glucocerebrosidase, the enzyme that hydrolyzes glucosylceramide to ceramide and glucose | Mutations cause Gaucher disease and increase Parkinson disease risk |
| SAPC (saposin C) | Activator protein that presents glucosylceramide to GBA1 | Deficiency leads to saposin C deficiency and lysosomal storage |
| GM2A | GM2 activator protein, involved in glycosphingolipid degradation | Mutations cause GM2 gangliosidosis |
| ABCC10 | Transporter that regulates glucosylceramide efflux and synthesis | Modulates drug resistance and lipid homeostasis |
| UGCG | Glucosylceramide synthase, synthesizes GlcCer, the substrate for catabolism | Balances anabolic and catabolic flux |
| ASAH1 | Acid ceramidase, degrades ceramide produced from GlcCer | Links glucosylceramide catabolism to ceramide signaling |
| SMPD1 | Acid sphingomyelinase, another lysosomal sphingolipid hydrolase | Defects cause Niemann-Pick disease |
| GALC | Galactocerebrosidase, degrades galactosylceramide, related pathway | Defects cause Krabbe disease |
| ARSA | Arylsulfatase A, degrades sulfatides | Defects cause metachromatic leukodystrophy |
| HEXA | Hexosaminidase A, degrades GM2 ganglioside | Defects cause Tay-Sachs disease |
| HEXB | Hexosaminidase B, degrades GM2 ganglioside | Defects cause Sandhoff disease |
| PSAP | Prosaposin, precursor of saposins A-D | Mutations affect multiple sphingolipid hydrolases |
| LIMP2 | Lysosomal integral membrane protein 2, transports GBA1 to lysosome | Regulates GBA1 localization and activity |
| TFEB | Transcription factor that promotes lysosomal biogenesis and function | Regulates expression of degradative enzymes |
| mTORC1 | Kinase complex that inhibits TFEB and lysosomal degradation | Links nutrient status to glucosylceramide catabolism |
| PI4KII | Phosphatidylinositol 4-kinase, produces Golgi phosphoinositides | Regulates glucosylceramide synthesis and indirectly catabolism |
| ABCA1 | Cholesterol and lipid transporter | May influence membrane lipid domains affecting GlcCer |
| NPC1 | Niemann-Pick C1, cholesterol transporter | Defects alter sphingolipid trafficking and catabolism |
How Is regulation of glucosylceramide catabolic process Regulated?
Regulation of glucosylceramide catabolic process is controlled at multiple levels. Nutrient-sensing pathways such as mTORC1 inhibit the transcription factor TFEB, reducing expression of lysosomal hydrolases including GBA1. Golgi-localized phosphoinositides modulate glucosylceramide synthesis, thereby affecting substrate availability for catabolism. ABCC10-mediated efflux at the plasma membrane and Golgi further tunes the pool of glucosylceramide. Additionally, nicotinamide can increase ceramide biosynthesis, indirectly influencing catabolic flux. These layers ensure that glucosylceramide breakdown is matched to cellular lipid demands.
regulation of glucosylceramide catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GBA1 | Gaucher disease, Parkinson disease | Knockout and point-mutation iPSC-derived neurons |
| SAPC | Saposin C deficiency | Knockout mice and patient fibroblasts |
| ABCC10 | Drug resistance, lipid homeostasis | Overexpression and knockout cell lines |
| UGCG | Gaucher-like lipid accumulation | Knockout and knock-in models |
| TFEB | Lysosomal dysfunction | Overexpression and knockout models |
Gaucher disease and lysosomal storage disorders
Biallelic mutations in GBA1 cause Gaucher disease, characterized by accumulation of glucosylceramide in macrophages. Impaired catabolism leads to hepatosplenomegaly, bone lesions, and anemia. Regulation of glucosylceramide catabolic process is therefore central to disease pathology, and therapies such as enzyme replacement and substrate reduction aim to restore balance.
Parkinson disease and neurodegeneration
Heterozygous GBA1 mutations are the most common genetic risk factor for Parkinson disease. Reduced glucocerebrosidase activity leads to glucosylceramide accumulation, alpha-synuclein aggregation, and neuronal dysfunction. Sphingolipid dysregulation is increasingly recognized in Alzheimer disease and other neurodegenerative conditions.
Renal fibrosis and metabolic disorders
Sphingolipid signaling, including glucosylceramide metabolism, contributes to renal fibrosis. Altered catabolism can promote fibrotic remodeling through ceramide-mediated pathways. Targeting this regulatory node may offer therapeutic benefits in chronic kidney disease.
Fungal pathogenesis and membrane domains
In fungi, sphingolipid-enriched domains rely on regulated glucosylceramide catabolism for membrane organization and virulence. Understanding these pathways can inform antifungal drug development.
From regulation of glucosylceramide catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GBA1 alter glucosylceramide catabolism? | CRISPR knockout of GBA1 in HeLa or iPSCs |
| Does a point mutation in GBA1 affect enzyme activity? | Point-mutation knock-in via CRISPR |
| Can a tagged GBA1 reveal lysosomal localization? | Knock-in of fluorescent tag (e.g., GFP) |
| Does ABCC10 overexpression change GlcCer efflux? | Overexpression of ABCC10 in HEK293 cells |
| Does TFEB activation increase catabolic gene expression? | Overexpression of TFEB or mTOR inhibition |
| Does Golgi phosphoinositide manipulation affect GlcCer levels? | Knockout of PI4KII or overexpression of phosphatases |
How to Study the regulation of glucosylceramide catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS lipidomics | Glucosylceramide and ceramide levels | Quantify catabolic flux in knockout cells |
| Enzyme activity assay | Glucocerebrosidase activity | Validate GBA1 mutations |
| Fluorescence microscopy | Subcellular localization of GBA1 and lipids | Assess lysosomal targeting |
| RNA-seq | Transcriptional changes in sphingolipid genes | Identify regulatory networks |
| Proteomics | Protein expression and modifications | Discover post-translational regulation |
| CRISPR screening | Gene essentiality and modifiers | Identify novel regulators of catabolism |
| Co-immunoprecipitation | Protein-protein interactions | Study saposin C-GBA1 binding |
| Flow cytometry | Lipid surface levels | Measure ABCC10-mediated efflux |
Lipidomics and mass spectrometry
Quantitative lipidomics using LC-MS/MS measures glucosylceramide and ceramide species to assess catabolic flux. This method is essential for validating regulatory effects in CRISPR models.
Enzyme activity assays
Fluorogenic or radiolabeled substrates measure glucocerebrosidase activity in cell lysates or purified fractions. These assays directly report on the catabolic step regulated by GO:2000752.
Imaging and subcellular localization
Fluorescence microscopy with tagged GBA1 or lipid probes visualizes lysosomal targeting and lipid distribution. Live-cell imaging can track glucosylceramide trafficking.
Transcriptomics and proteomics
RNA-seq and proteomics identify changes in sphingolipid enzyme expression upon regulatory perturbations. These approaches reveal transcriptional and post-translational networks.
How CRISPR Can Be Used to Study GO:2000752 regulation of glucosylceramide catabolic process
Knockout
CRISPR knockout of GBA1, UGCG, or ABCC10 creates cell models to study loss-of-function effects on glucosylceramide catabolism. These models reveal substrate accumulation and compensatory pathways.
Point Mutation
Introducing disease-associated point mutations (e.g., GBA1 N370S) via CRISPR base editing or HDR allows precise assessment of enzyme activity and regulation. Such models mimic patient genotypes.
Knock-in
Knock-in of fluorescent or affinity tags at endogenous loci enables real-time tracking of GBA1 localization and interactions. This approach preserves native regulation.
Overexpression
CRISPR activation or cDNA overexpression of TFEB, ABCC10, or GBA1 tests gain-of-function effects on catabolic flux. Overexpression models help identify rate-limiting steps.
How EDITGENE Supports regulation of glucosylceramide catabolic process Research
Researchers studying regulation of glucosylceramide catabolic process-related genes often need to determine whether a candidate gene is causally involved in lipid breakdown or merely correlated with it. EDITGENE provides the full spectrum of CRISPR cell model engineering and screening services to answer such questions with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for regulation of glucosylceramide catabolic process research.
Frequently Asked Questions About regulation of glucosylceramide catabolic process
What is GO:2000752?
GO:2000752 is the Gene Ontology term for regulation of glucosylceramide catabolic process, defined as any process that modulates the frequency, rate or extent of glucosylceramide breakdown.
What genes are involved in regulation of glucosylceramide catabolic process?
Key genes include GBA1, SAPC, GM2A, ABCC10, UGCG, ASAH1, and TFEB, among others.
What is glucosylceramide catabolic process?
It is the enzymatic breakdown of glucosylceramide into ceramide and glucose, primarily in the lysosome.
How is glucosylceramide catabolism regulated?
It is regulated by Golgi phosphoinositides, ABCC10-mediated efflux, mTORC1-TFEB signaling, and transcriptional control.
What diseases are linked to glucosylceramide catabolism?
Gaucher disease, Parkinson disease, renal fibrosis, and other neurodegenerative disorders.
Which enzyme breaks down glucosylceramide?
Glucocerebrosidase (GBA1) hydrolyzes glucosylceramide to ceramide and glucose.
How can CRISPR be used to study this process?
CRISPR knockout, point mutation, knock-in, and overexpression models can dissect the causal roles of regulatory genes.
What are the synonyms for GO:2000752?
Synonyms include regulation of glucosylceramide breakdown, regulation of glucosylceramide catabolism, and regulation of glucosylceramide degradation.
What is the role of saposin C in glucosylceramide catabolism?
Saposin C is an activator protein that presents glucosylceramide to GBA1 for hydrolysis.
How does ABCC10 regulate glucosylceramide?
ABCC10 differentially regulates glucosylceramide synthesis and efflux at the Golgi and plasma membrane.
Conclusion
GO:2000752, regulation of glucosylceramide catabolic process, is a critical biological process that controls the breakdown of glucosylceramide into ceramide and glucose. Its dysregulation underlies lysosomal storage disorders, neurodegeneration, and metabolic diseases. Advances in CRISPR-based models and lipidomics are accelerating the discovery of regulatory mechanisms and therapeutic targets. EDITGENE offers comprehensive services to support this research, from knockout to library screening.
References
- 1. Gault CR et al.. 2010. An overview of sphingolipid metabolism: from synthesis to breakdown.. Adv Exp Med Biol 688:1-23 PMID: 20919643
- 2. Ishibashi Y et al.. 2018. Regulation of glucosylceramide synthesis by Golgi-localized phosphoinositide.. Biochem Biophys Res Commun 499(4):1011-1018 PMID: 29627573
- 3. Tanno O et al.. 2000. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier.. Br J Dermatol 143(3):524-31 PMID: 10971324
- 4. Iqbal J et al.. 2023. Differential Regulation of Glucosylceramide Synthesis and Efflux by Golgi and Plasma Membrane Bound ABCC10.. Nutrients 15(2) PMID: 36678216
- 5. Santos FC et al.. 2020. Sphingolipid-enriched domains in fungi.. FEBS Lett 594(22):3698-3718 PMID: 33141925
- 7. Huwiler A et al.. 2018. Sphingolipid signaling in renal fibrosis.. Matrix Biol 68-69:230-247 PMID: 29343457
- 8. Alessenko AV et al.. 2020. Exploring Sphingolipid Implications in Neurodegeneration.. Front Neurol 11:437 PMID: 32528400
